Ecuador

Reimbursed Care Access

Ecuador maintains a restrictive national drug control framework that classifies most classical psychedelics as controlled psychotropic substances, with no routine public reimbursement or broad medical approvals for psilocybin, MDMA, DMT, 5-MeO-DMT, mescaline, ibogaine or 2C‑X. Ketamine is an established medical anesthetic and is used in clinical settings (including off‑label psychiatric/analgesic uses); esketamine (Spravato) does not appear to have a national registered/covered pathway comparable to high‑income jurisdictions, and any access would depend on private clinics, institutional procurement and ARCSA registration requirements. Indigenous ceremonial use of ayahuasca is culturally tolerated in parts of Ecuador, but its active constituent (DMT) remains controlled under national narcotics law and is not part of reimbursed public mental‑health care.